↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant(2008).„Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”.Annual Reports in Computational Chemistry4: 217-241.DOI:10.1016/S1574-1400(08)00012-1.
↑Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP.(2012).„ChEMBL: a large-scale bioactivity database for drug discovery”.Nucleic Acids Res40(Database issue): D1100-7.DOI:10.1093/nar/gkr777.PMID21948594.edit
↑Cosford,N. D.;Bleicher,L.;Vernier,J. M.;Chavez-Noriega,L.;Rao,T. S.;Siegel,R. S.;Suto,C.;Washburn,M.i dr..(2000).„Recombinant human receptors and functional assays in the discovery of altinicline (SIB-1508Y), a novel acetylcholine-gated ion channel (nAChR) agonist”.Pharmaceutica acta Helvetiae74(2–3): 125–130.DOI:10.1016/S0031-6865(99)00024-2.PMID10812948.
↑Wagner,F.;Comins,D.(2006).„Expedient five-step synthesis of SIB-1508Y from natural nicotine”.The Journal of Organic Chemistry71(22): 8673–8675.DOI:10.1021/jo0616052.PMID17064057.
↑Rao,T.;Adams,P.;Correa,L.;Santori,E.;Sacaan,A.;Reid,R.;Cosford,N.(2008).„Pharmacological characterization of (S)-(2)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine HCl (SIB-1508Y, Altinicline), a novel nicotinic acetylcholine receptor agonist”.Brain Research1234: 16–24.DOI:10.1016/j.brainres.2008.07.063.PMID18692487.
↑The Parkinson Study Group. Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease. Neurology. 2006;66:408-410. DOI:10.1212/01.wnl.0000196466.99381.5c
↑Wagner,Florence F.;Comins,Daniel L.(2006).„Expedient Five-Step Synthesis of SIB-1508Y from Natural Nicotine”.The Journal of Organic Chemistry71(22): 8673.DOI:10.1021/jo0616052.PMID17064057.